

GRANT AGREEMENT



Parties to this agreement:

Danmarks Bløderforening

Att: Karen Binger Holm

Blekinge Boulevard 2

2630 Taastrup

CVR: 11802990

("Recipient")

Novo Nordisk Denmark A/S

Att.: Søren Beicker Sørensen

Kay Fiskers Plads 10, 7 floor

2300 København S

CVR No. 38180045

("Novo Nordisk")

1. Summary

1.1 Recipient's request for support. The appendix titled "Recipient's request for support" details the specifics of the Recipient's activity(ies) ("the Activity") supported by the grant and purpose of the Activity. Novo Nordisk has decided to support the recipient's request as part of its commitment to advance healthcare and science.

Title of Activity	One board member's participation at World Federation of Hemophilia (WFH) Congress taking place 19-22th April 2026, Kuala Lumpur, Malaysia
Purpose of the Activity	The recipient shall use the grant only for the healthcare-related purpose of one board member's participation in WFH Congress. <i>The recipient's purpose must not involve promotion of any pharmaceutical product.</i>
Grant amount	Novo Nordisk will provide 14 536 DKK, including added tax if applicable, to support the Recipient's request. Novo Nordisk will not make any non-financial transfers of value.
Agreement Duration	This agreement starts on the last signature date below and expires after all obligations are fulfilled, unless terminated earlier.

2. Recipient's Duties

2.1 Compliance with law and ethics. The Recipient shall comply with all applicable laws, rules, regulations, and professional standards, including those related to ethical business practices, bribery and corruption, among others. The Recipient will hold Novo Nordisk harmless against any claim or suit that arises in relation to any deviation from the above mentioned that is not due to any act or omission by Novo Nordisk.

2.2 Carry out the Activity with proper conduct. The Recipient shall carry out the Activity independently and without Novo Nordisk influence, and in compliance with Novo Nordisk standards and industry codes such as IFPMA, EFPIA and ENLI (Etisk Nævn for Lægemiddelindustrien). Such proper conduct of the Activity includes, but is not limited to:

No use of funds for entertainment	Do not use the grant for leisure or social activities
No use of product names	Do not use trade and advertising names of medicinal products in any content or materials used for the Activity
Select qualified participants	Apply appropriate criteria to select participants in the Activity, including that any speakers, facilitators, and chairpersons are experts in the professional fields relevant to the Activity
Reasonable payment	If grant is used to provide payments to third parties, apply a reasonable rate, including following Fair Market Value for any payments to Healthcare Professionals (hereinafter refer to as 'HCPs') and patients

Reasonable choice of venue	Hold activities in a location suitable for business meetings with modest hospitality
Reasonable travel	If grant is used for Activity-related travel, carry out within reasonable time and cost
Transparency about support towards participants	The invitation for the event must clearly state that the event is being supported by one or more pharmaceutical companies.
Acknowledgment of obligations towards ENLI	The Recipient acknowledges that Novo Nordisk must report the grant to ENLI (Etisk Nævn for Lægemedelindustrien) in accordance with ENLI's Patient Organisation Code.

2.3 Internal approvals. The Recipient shall obtain all necessary approvals related to the receipt of the grant.

2.4 Provide documentation within 1 month. The Recipient shall provide Novo Nordisk with documentation that the grant was used for its intended purpose, within 1 month of completion of the Activity. Novo Nordisk may request additional detailed documentation as needed.

2.5 Inform Novo Nordisk of changes. The Recipient shall inform Novo Nordisk of any changes affecting the request for support. Novo Nordisk may increase, decrease, withdraw or require full or partial repayment of the grant as a result of the changes. In the case of repayment, the Recipient shall refund Novo Nordisk the requested amount within 14 days.

2.6 Refund unspent amounts. The Recipient shall refund Novo Nordisk any amounts not spent for the requested purposes, within 14 days after complete documentation of the Activity is provided.

2.7 Disclose Novo Nordisk as grant provider. The Recipient shall mention Novo Nordisk as the provider of the grant in educational materials developed through the grant, as well as in any public communications or advertising related to the Activity.

2.8 Required public disclosures. Novo Nordisk will publish information relating to this grant on Novo Nordisk's website (www.novonordisk.dk). According to Danish regulation Novo Nordisk may in addition make this Grant Agreement publicly available. The Recipient shall provide to Novo Nordisk upon request all information reasonably required for Novo Nordisk's compliance with legal and/or regulatory requirements for contracting, tracking and disclosing transfer of values (ToVs) to the Recipient.

The Recipient will publish information on the grant on the Recipient's webpage. The information includes the grants amount and, if applicable, any in kind transfer, cf. the Danish Pharmaceutical Promotional Act (Reklamebekendtgørelsen) § 21. The information must be available on the Recipient's webpage no later than one (1) month after the Recipient received the Grant. The information must be publicly available for at least two (2) years.

2.9 Do not use Novo Nordisk branding without approval. The Recipient may not use Novo Nordisk's logo, trademarks or other corporate identity marks or materials without written approval of the use from Novo Nordisk.

2.10 Allow Novo Nordisk to use Recipient's logo. The Recipient permits Novo Nordisk to use the Recipient's logo, trademarks or other corporate identity marks in any public communications or advertising related to Novo Nordisk's grant.

3. Payment and Invoice Requirements

3.1 Payment after receipt of invoice. Novo Nordisk will send payment after receipt of invoice to the Recipient's bank account via electronic transfer within 30 days of receiving a complete invoice. Send completed PDF invoice to: AP-Novo-Repas@novonordisk.com. Include the below information on the invoice:

- Recipient name and address
- Bank account for electronic payment: Account holder name, account number (IBAN), bank name and address, routing number or code (SWIFT/BIC in EU, ABA/ACH in USA)
- Date of invoice
- The Title of Activity and dates of activities covered by the invoice
- Grant amount payable
- VAT or other tax amount payable (include separately from payment amount)
- Name of Novo Nordisk entity and address as stated in the introduction of this Agreement
- Novo Nordisk recipient of invoice as included below:

Name of Novo Nordisk invoice recipient Søren Becker Sørensen (SBSB)

4. Other Terms and Conditions

- 4.1 Disclosure of Transfers of Value.** To comply with applicable transparency requirements, Novo Nordisk will collect and may disclose personal information, transfers of value and details of its payment to Healthcare Professionals (“HCPs”) and Healthcare Organizations (“HCOs”). In addition to the payment amount, such disclosure may also include: Name, address, contact details, nature of relationship with Novo Nordisk, tax number or unique identifier.
 - 4.2 No conflict of interest.** Recipient states it is not aware of any conflict of interest related to its acceptance of the grant and shall promptly inform Novo Nordisk if such conflict of interest is discovered.
 - 4.3 Compliance hotline.** The Recipient can report suspected misconduct through the Novo Nordisk compliance hotline. Information about using the hotline and examples of what to report can be found at [Report suspected misconduct \(novonordisk.com\)](https://www.novonordisk.com/report-suspected-misconduct).
 - 4.4 No incentive to prescribe or recommend.** The payments made by Novo Nordisk indicate no incentive or obligation for the Recipient to prescribe, recommend or otherwise support Novo Nordisk’s products or services.
 - 4.5 Termination for breach.** Either party may terminate this contract immediately upon material breach by the other party.
 - 4.6 Governing Law and Dispute Resolution.** The laws of Denmark govern this agreement, disregarding choice of law rules. If a dispute cannot be settled by negotiation between parties, it will be settled by the ordinary courts in that country.
5. **Attachments**
The following attachments are part of this agreement
- Attachment A: Recipient’s request for support incl, budget

6. Agreed to and Accepted by:

Date: 10 marts 2026

Date: 06 marts 2026

On behalf of Recipient: Signed by:
Karen Binger Holm
46A0A742616D4F7...

On behalf of Novo Nordisk: DocuSigned by:
Søren Beicker Sørensen
80BA49E04F66467...

Name: Karen Binger Holm

Name: Søren Beicker Sørensen

Title: Sekretariatsleder

Title: Sr Public Affairs Manager

Appendix A: Recipient's Request for Support**1. Copy of the Recipient's grant request incl budget**

Novo Nordisk Danmark
Att.: Christian Klyver Tikkanen
ctik@novonordisk.com

D. 5. januar 2026

Ansøgning om støtte til Danmarks Bløderforenings deltagelse i WFH kongres 2026

Med denne ansøgning søger Danmarks Bløderforening om støtte til et bestyrelsesmedlems deltagelse i World Federation of Hemophila's kongres d. 19-22 i Kuala Lumpur, Malaysia, med ankomst d. 18. april og afgang d. 23. april 2026, i alt 14.536 kr.

Som forening for mennesker med sjældne blødersygdomme er det vigtigt for Danmarks Bløderforening at være en del af det internationale blødersamfund og danne netværk og dele viden på tværs af grænser og kontinenter. Derfor prioriterer foreningen hvert år at deltage i internationale møder og seminarer. Ikke mindst i lyset af de mange forskellige nye behandlinger, der kommer på markedet i disse år, og mere fokus på behandlingsmuligheder af flere blødersygdomme, vil Danmarks Bløderforening gerne deltage i WFH kongressen i 2026 med tre bestyrelsesmedlemmer.

Med denne ansøgning søges om tilskud til at dække udgifter til konference, ophold og forplejning, samt transport for én person:

Udgift pr. person	Pris DKK
Konferencepris	2.147
Hotel, 5 nætter*	2.100
Fly, tur-retur - estimat	7.165
Forplejning - 531 kr., 4 dage**	2.124
Transport, lokalt - estimat	1.000
I alt	14.536

*Holiday Inn Express Kuala Lumpur City Centre

**Statens takst i 2026 (625 kr.), fratrukket 15 % da morgenmad er inkluderet i hotelpris

Deltagerne skriver referater fra konferencen, som formidles i artikelform på foreningens hjemmeside og sociale medier, så alle foreningens medlemmer får del i den viden, der er opnået på mødet. Al støtte til dette formål er velkommen og modtages med tak. Hvis der er spørgsmål til ansøgningen, står jeg naturligvis til rådighed.

Venlig hilsen
Karen Binger Holm
Sekretariatsleder

SE nr.: 11 80 29 90
Sydbank, Reg. nr.: 7040, Konto nr.: 1106847